This Week in HIV Research: Let's Get Real About Treatment Efficacy

This Week in HIV Research: Let's Get Real About Treatment Efficacy

1 of 5
Next >

Many of the research findings that have formed the pillars of our HIV treatment evolution since the 1980s were derived from well-constructed and tightly controlled studies, in which potential participants were excluded based on any of a host of factors. These restrictions are critical characteristics: They allow us to remove background noise and assess the true safety and efficacy of our treatment options and strategies. But they also often leave a critical question answered: How well will this treatment truly work in the real world?

Most of our featured studies this week seek to answer that question across a range of important topics, including:

  • The efficacy of modern-era antiretroviral regimens in real-world settings as opposed to phase 3 trials.
  • The correlation between parent-child communication about HIV and pre-exposure prophylaxis (PrEP) awareness among adolescent men who have sex with men.
  • The feasibility of immune-checkpoint inhibitors as cancer therapy in people receiving HIV treatment.
  • The relationship between AIDS-defining illness history and mortality risk among people diagnosed with cancer.

Read on, and let's get real about each of these study findings. To beat HIV, you have to follow the science!

Barbara Jungwirth is a freelance writer and translator based in New York. Follow Barbara on Twitter: @reliabletran.

Myles Helfand is the executive editor and general manager of TheBody and TheBodyPRO. Follow Myles on Twitter: @MylesatTheBody.

Image Credit: Ingram Publishing via Thinkstock

Many of the research findings that have formed the pillars of our HIV treatment evolution since the 1980s were derived from well-constructed and tightly controlled studies, in which potential participants were excluded based on any of a host of factors. These restrictions are critical characteristics: They allow us to remove background noise and assess the true safety and efficacy of our treatment options and strategies. But they also often leave a critical question answered: How well will this treatment truly work in the real world?

Most of our featured studies this week seek to answer that question across a range of important topics, including:

  • The efficacy of modern-era antiretroviral regimens in real-world settings as opposed to phase 3 trials.
  • The correlation between parent-child communication about HIV and pre-exposure prophylaxis (PrEP) awareness among adolescent men who have sex with men.
  • The feasibility of immune-checkpoint inhibitors as cancer therapy in people receiving HIV treatment.
  • The relationship between AIDS-defining illness history and mortality risk among people diagnosed with cancer.

Read on, and let's get real about each of these study findings. To beat HIV, you have to follow the science!

Barbara Jungwirth is a freelance writer and translator based in New York. Follow Barbara on Twitter: @reliabletran.

Myles Helfand is the executive editor and general manager of TheBody and TheBodyPRO. Follow Myles on Twitter: @MylesatTheBody.

Image Credit: Ingram Publishing via Thinkstock